The company expects to only pay a tax rate of 9 percent this year, which will free up a lot of cash. Source: BioSpace

A look at three big biotech companies that have big catalysts this year that could have a, you guessed it, big effect. Source: BioSpace

The new data supports further development of SAGE-217 in disorders associated with disruption of normal sleep. Source: BioSpace

It seems that the primary news surrounding Alzheimer's disease research has been nothing but negative for years. Source: BioSpace

A look at whether the new tax reform will really spur a M&A spending spree for drugmakers. Source: BioSpace

MannKind could be sent to dilute shares in a significant manner, warns Maxim analyst Jason Kolbert in a research note released today. Source: BioSpace

Artelo Biosciences and the NEOMED Institute announced today that they have entered into an exclusive global option and license agreement for NEO1940. Source: BioSpace

With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be. Source: BioSpace

The SEC filed a suit against “one or more unknown traders” while it seeks to identify the perpetrators. Source: BioSpace

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD. Source: BioSpace